Published in Biol Blood Marrow Transplant on January 05, 2017
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol (1985) (1986) 8.01
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2010) 4.56
Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation (2010) 3.83
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol (2010) 2.18
An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J (2014) 2.01
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr (2014) 1.88
Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncol (2008) 1.79
Age-related declines in maximal aerobic capacity in regularly exercising vs. sedentary women: a meta-analysis. J Appl Physiol (1985) (1997) 1.79
Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol (2002) 1.78
EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation (2012) 1.67
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol (2012) 1.61
Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest (2000) 1.60
Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood (2012) 1.58
Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. Cancer (2010) 1.40
Strain imaging in echocardiography: methods and clinical applications. Int J Cardiovasc Imaging (2009) 1.37
Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant (2010) 1.33
Meta-analysis of the age-associated decline in maximal aerobic capacity in men: relation to training status. Am J Physiol Heart Circ Physiol (2000) 1.31
Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant (2013) 1.30
Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship. J Clin Oncol (2012) 0.97
Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study. Bone Marrow Transplant (2013) 0.96
Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study. Bone Marrow Transplant (2014) 0.93
Cardiovascular complications in long-term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol (2012) 0.91
Regulation of the structural remodelling of the myocardium: from hypertrophy to heart failure. Eur Heart J (1994) 0.90
Cardiovascular disease in survivors of hematopoietic cell transplantation. Cancer (2013) 0.90
Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study. Clin Lymphoma Myeloma Leuk (2014) 0.84
Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2014) 0.83
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin. Mol Cancer Ther (2015) 0.82
Phase I Trial of Total Marrow and Lymphoid Irradiation Transplant Conditioning in Patients with Relapsed/Refractory Acute Leukemia. Biol Blood Marrow Transplant (2017) 0.81
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. Biol Blood Marrow Transplant (2016) 0.80
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biol Blood Marrow Transplant (2016) 0.79
Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant (2015) 0.75
Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant (2015) 0.75
Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant (2015) 0.75
HyperCVAD Chemotherapy in Mantle Cell Lymphoma Patients is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure, Despite Plerixafor Rescue. Biol Blood Marrow Transplant (2017) 0.75
Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology. Biol Blood Marrow Transplant (2017) 0.75